BioVersys, SARomics Biostructures deal

BioVersys and SARomics partnered to discover small molecules that block the transcriptional activation of undisclosed resistance genes to restore the efficacy and antibiotic activity of undisclosed marketed drugs. The companies said they will combine their "highly complementary" technology modules, expertise and resources in the project, dubbed SARTRIC. BioVersys will have full rights to commercialize resulting products. ...